Mga Batayang Estadistika
| LEI | 549300C0KZP8EYROLL02 |
| CIK | 1730463 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Autolus Therapeutics plc - Depositary Receipt (Common Stock)
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 12, 2025 |
Autolus Therapeutics plc - 2025 Employee Share Purchase Plan ex-101xautolustherapeuti 303197006 v5 Exhibit 10.1 AUTOLUS THERAPEUTICS PLC 2025 EMPLOYEE SHARE PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: MAY 20, 2025 APPROVED BY THE SHAREHOLDERS: JUNE 26, 2025 1. GENERAL; PURPOSE. (a) The Plan provides a means by which Eligible Employees of the Company and certain Designated Companies may be given an opportunity to purchase Shares. The Plan permits the Co |
|
| August 12, 2025 |
autlex-991pr120825 Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates August 12, 2025 at 7:00 AM EDT Company reports Q2 2025 AUCATZYL® net product revenue of $20. |
|
| August 12, 2025 |
Autolus Therapeutics plc - 2025 ex-101xautolustherapeuti 303197006 v5 Exhibit 10.1 AUTOLUS THERAPEUTICS PLC 2025 EMPLOYEE SHARE PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: MAY 20, 2025 APPROVED BY THE SHAREHOLDERS: JUNE 26, 2025 1. GENERAL; PURPOSE. (a) The Plan provides a means by which Eligible Employees of the Company and certain Designated Companies may be given an opportunity to purchase Shares. The Plan permits the Co |
|
| August 12, 2025 |
autlex-992cp120825 Q2 2025 Financial Results and Business Updates August 12, 2025 Autolus. |
|
| August 12, 2025 |
Autolus Therapeutics plc - 2025 ex-102xautolustherapeuti Exhibit 10.2 AUTOLUS THERAPEUTICS PLC UK SHARESAVE SUB-PLAN TO THE AUTOLUS THERAPEUTICS PLC 2025 EMPLOYEE SHARE PURCHASE PLAN Adopted by the Board on May 20, 2025 Registered with HM Revenue & Customs on under number . CONTENTS Clause Page 1. INTERPRETATION....................................................................................................................... |
|
| August 12, 2025 |
Autolus Therapeutics plc - 2025 UK Sharesave Sub-plan ex-102xautolustherapeuti Exhibit 10.2 AUTOLUS THERAPEUTICS PLC UK SHARESAVE SUB-PLAN TO THE AUTOLUS THERAPEUTICS PLC 2025 EMPLOYEE SHARE PURCHASE PLAN Adopted by the Board on May 20, 2025 Registered with HM Revenue & Customs on under number . CONTENTS Clause Page 1. INTERPRETATION....................................................................................................................... |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2025 Autolus Therapeutics plc (Exact name of registrant as specified in its Charter) England and Wales 001-38547 Not applicable (State or other jurisdiction of incorporatio |
|
| August 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001 |
|
| August 12, 2025 |
Table of contents Filed pursuant to Rule 424(b)(3) Registration No. 333-287097 PROSPECTUS SUPPLEMENT NO. 3 (To the prospectus dated May 15, 2025) Up to 54,584,250 American Depositary Shares Representing 54,584,250 Ordinary Shares Offered by Selling Securityholders This prospectus supplement supplements the prospectus, dated May 15, 2025 (the “Prospectus”), which forms a part of our registration st |
|
| June 30, 2025 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-287097 PROSPECTUS SUPPLEMENT NO. 2 (To the prospectus dated May 15, 2025) Up to 54,584,250 American Depositary Shares Representing 54,584,250 Ordinary Shares Offered by Selling Securityholders This prospectus supplement supplements the prospectus, dated May 15, 2025 (the “Prospectus”), which forms a part of our registration statement on Form S- |
|
| June 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2025 Autolus Therapeutics plc (Exact name of registrant as specified in its Charter) England and Wales 001-38547 Not applicable (State or other jurisdiction of incorporation |
|
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2025 Autolus Therapeutics plc (Exact name of registrant as specified in its Charter) England and Wales 001-38547 Not applicable (State or other jurisdiction of incorporation o |
|
| June 2, 2025 |
Form of Proxy - Annual General Meeting to be held on 26 June 2025 Kindly Note: This form is issued only to the addressee(s) and is specific to the unique designated account printed hereon. |
|
| June 2, 2025 |
statement of liabilities parent company statement of liabilities parent company |
|
| June 2, 2025 |
1 THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to the action to be taken, please seek your own independent financial advice from your stockbroker, solicitor, accountant or other appropriately authorised independent financial adviser. If you have recently sold or transferred all of your ordinary shares in Autolus Therapeutics plc, you should forward t |
|
| May 30, 2025 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-287097 PROSPECTUS SUPPLEMENT NO. 1 (To the prospectus dated May 15, 2025) Up to 54,584,250 American Depositary Shares Representing 54,584,250 Ordinary Shares Offered by Selling Securityholders This prospectus supplement supplements the prospectus, dated May 15, 2025 (the “Prospectus”), which forms a part of our registration statement on Form S- |
|
| May 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2025 Autolus Therapeutics plc (Exact name of registrant as specified in its Charter) England and Wales 001-38547 Not applicable (State or other jurisdiction of incorporation o |
|
| May 15, 2025 |
Up to 54,584,250 American Depositary Shares Representing 54,584,250 Ordinary Shares 424B3 Table of Contents Filed pursuant to Rule 424(b)(3) File No. 333-287097 Up to 54,584,250 American Depositary Shares Representing 54,584,250 Ordinary Shares This prospectus relates to the resale from time to time by the selling securityholders identified in this prospectus, of up to 54,584,250 American Depositary Shares, or ADSs, consisting of (i) 51,318,944 ADSs, representing 51,318,944 of ou |
|
| May 13, 2025 |
The MediaWorks 191 Wood Lane White City London W12 7FP United Kingdom VIA EDGAR CORRESP The MediaWorks 191 Wood Lane White City London W12 7FP United Kingdom VIA EDGAR May 13, 2025 U. |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 00 |
|
| May 8, 2025 |
autlex-992cp080525 Q1 2025 Financial Results and Business Updates May 8, 2025 Autolus. |
|
| May 8, 2025 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Autolus Therapeutics plc (Exact Name of Registrant as Specified in its Charter) Table 1 – Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount |
|
| May 8, 2025 |
As filed with the Securities and Exchange Commission on May 8, 2025 S-1 Table of Contents As filed with the Securities and Exchange Commission on May 8, 2025 Registration No. |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 Autolus Therapeutics plc (Exact name of registrant as specified in its Charter) England and Wales 001-38547 Not applicable (State or other jurisdiction of incorporation or |
|
| May 8, 2025 |
Exhibit 10.2 AUTOLUS THERAPEUTICS PLC OPTION GRANT NOTICE (2025 INDUCEMENT PLAN) Autolus Therapeutics plc (the “Company”), pursuant to its 2025 Inducement Plan (the “Plan”), hereby grants to Optionholder the option described in this grant notice at the exercise price set forth below (the “Option”). This Option is subject to all of the terms and conditions as set forth in this Option Grant Notice ( |
|
| May 8, 2025 |
Exhibit 10.3 AUTOLUS THERAPEUTICS PLC RESTRICTED SHARE UNIT GRANT NOTICE (2025 INDUCEMENT PLAN) Autolus Therapeutics plc (the “Company”), pursuant to Section 6(b) of the Company’s 2025 Inducement Plan (the “Plan”), hereby awards to Participant Restricted Share Units (“RSUs” or “Restricted Share Units”) described below (sometimes referred to as the “Award”). The Award is subject to all of the terms |
|
| May 8, 2025 |
autlex-991pr080525 Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates May 8, 2025 at 7:00 AM EDT Company reports Q1 2025 AUCATZYL® net product revenue of $9. |
|
| May 8, 2025 |
utolus Therapeutics plc - 2025 In Exhibit 10.1 Autolus Therapeutics plc 2025 Inducement Plan Adopted by the Board: March 27, 2025 1.General. (a)Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) or 5635(c)(3), if applicable, and the related guidance under Nasdaq IM 5635-1. A person |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2025 Autolus Therapeutics plc (Exact name of registrant as specified in its Charter) England and Wales 001-38547 Not applicable (State or other jurisdiction of incorporation |
|
| April 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2025 Autolus Therapeutics plc (Exact name of registrant as specified in its Charter) England and Wales 001-38547 Not applicable (State or other jurisdiction of incorporat |
|
| March 20, 2025 |
autlex-991pr200325 Exhibit 99.1 1 Autolus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates • AUCATZYL® (obecabtagene autoleucel) U.S. commercial launch progressing on track with 33 authorized treatment centers as of March 19, 2025, following US FDA approval on November 8, 2024 • Obe-cel MHRA and EMA marketing authorizations expected in H2 2025 • Initial |
|
| March 20, 2025 |
Subsidiaries of the registrant. Exhibit 21.1 Autolus Therapeutics plc List of Subsidiaries Subsidiary Jurisdiction Autolus Holdings (UK) Limited England and Wales Autolus Limited England and Wales Autolus Inc. Delaware Autolus GmbH Germany Autolus Switzerland AG Switzerland |
|
| March 20, 2025 |
Q4 2024 Financial Results and Business Updates 20 March 2025 Autolus.com For Investor communication only. Not for use in product promotion. Not for further distribution. Exhibit 99.2 Disclaimer These slides contain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are |
|
| March 20, 2025 |
Amended and Restated Insider Trading and Window Period Policy exhibit191-insidertradin 1. 180019795 v1 AUTOLUS THERAPEUTICS PLC INSIDER TRADING AND WINDOW PERIOD POLICY (REVISED OCTOBER 16, 2020) INTRODUCTION During the course of your relationship with AUTOLUS THERAPEUTICS PLC (“Autolus”), you may receive important information that is not yet publicly available (“inside information”) about Autolus or other publicly traded companies that Autolus has business |
|
| March 20, 2025 |
As filed with the Securities and Exchange Commission on March 20, 2025 POS AM Table of Contents As filed with the Securities and Exchange Commission on March 20, 2025 Registration No. |
|
| March 20, 2025 |
As filed with the Securities and Exchange Commission on March 20, 2025 Table of Contents As filed with the Securities and Exchange Commission on March 20, 2025 Registration No. |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2025 Autolus Therapeutics plc (Exact name of registrant as specified in its Charter) England and Wales 001-38547 Not applicable (State or other jurisdiction of incorporation |
|
| March 20, 2025 |
Table of contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to Commission file number: 001-38547 Autolus |
|
| March 20, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Autolus Therapeutics plc (Exact Name of Registrant as Specified in its Charter) Table 1 – Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be Paid Equity Ordinary shares, nominal value $0. |
|
| March 20, 2025 |
Amended Management Incentive Compensation Plan exhibit1020-armanagement Exhibit 10.20 1 Management Incentive Compensation Plan (effective March 1, 2025) 1. Purpose of the Plan The Management Incentive Compensation Plan (the “Plan”) of Autolus Therapeutics plc and its group companies (collectively, “Autolus”) is designed to offer incentive compensation to officers and managers of Autolus (the “Associates”) by rewarding the achievement of corpor |
|
| March 20, 2025 |
Exclusive Distribution Agreement, effective as of exhibit1021-cardinalheal Exhibit 10.21 P a g e | 1 This document is confidential. Disclosure to third parties not permitted. Autolus/Cardinal Health: Distribution Services Agreement This Distribution Services Agreement (together with all attached Exhibits, the “Agreement”), effective as of the last date of signature (the “Effective Date”), is entered into by and between: 1) Autolus, Inc. with offi |
|
| January 13, 2025 |
Developing Next Generation Programmed T Cell Therapies January 2025 Autolus.com Disclaimer These slides contain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as “may,” “will,” “could,” “ex |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 Autolus Therapeutics plc (Exact name of registrant as specified in its Charter) England and Wales 001-38547 Not applicable (State or other jurisdiction of incorporati |
|
| November 14, 2024 |
EX-99.1 2 d901415dex991.htm EX-99.1 Exhibit 99.1 AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Ordinary Shares (represented by ADS, each of which represents one Ordinary Share) of Autolus Th |
|
| November 14, 2024 |
SC 13G/A 1 d901415dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7)* Autolus Therapeutics plc (Name of Issuer) American Depositary Shares and Ordinary Shares, nominal value $0.000042 per share (Title of Class of Securities) 05280R 100** (CUSIP Number) December 31, 2023 (Date of Event |
|
| November 14, 2024 |
As filed with the U.S. Securities and Exchange Commission on November 14, 2024 As filed with the U.S. Securities and Exchange Commission on November 14, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Autolus Therapeutics plc (Exact name of registrant as specified in its charter) England and Wales Not applicable (State or other jurisdiction of Incorporation |
|
| November 14, 2024 |
SC 13G/A 1 tm2427604d3sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Autolus Therapeutics plc (Name of Issuer) Ordinary Shares, nominal value $0.000042 per share** (Title of Class of Securities) 05280R100*** (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of |
|
| November 14, 2024 |
SC 13G/A 1 deeptrack-autl093024a3.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Autolus Therapeutics PLC (Name of Issuer) American Depositary Shares, each representing one ordinary share, nominal value $0.000042 per share (Title of Class of Securities) 05280R100 (CUSIP Number) September 30, 2024 |
|
| November 14, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Autolus Therapeutics plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered(2) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary shares Other 10,644,770(3) $3. |
|
| November 12, 2024 |
autlex-991pr121124 Autolus Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates November 12, 2024 at 7:00 AM EST AUCATZYL® (obecabtagene autoleucel) approved by US FDA on November 8, ahead of target PDUFA date of November 16; US commercial launch initiated BLA approval triggers $30m milestone payment to Autolus from Blackstone Marketing authorizations for obe-cel under review with both the MHRA EMA Matthias Will M. |
|
| November 12, 2024 |
Amended Management Incentive Compensation Plan EX-10.4 Management Incentive Compensation Plan (October 2024) 1. Purpose of the Plan The Management Incentive Compensation Plan (the “Plan”) of Autolus Therapeutics plc and its group companies (collectively, “Autolus”) is designed to offer incentive compensation to officers and managers of Autolus (the “Associates”) by rewarding the achievement of corporate goals and specifically measured personal |
|
| November 12, 2024 |
Email: [***] 4171312.18 Dated 2024 FORGE LIFE SCIENCES NOMINEE I LTD AND FORGE LIFE SCIENCES NOMINEE 2 LTD and AUTOLUS LIMITED and AUTOLUS THERAPEUTICS PLC Capital Contribution Deed relating to premises known as The Nucleus Marshgate, Stevenage SG1 1FR formerly known as part of The Marshgate Car Park, Stevenage EX-10.1 4171312.18 1 THIS DEED is dated the day of 2024 PARTIES (1) Forge Life Sciences |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 Autolus Therapeutics plc (Exact name of registrant as specified in its Charter) England and Wales 001-38547 Not applicable (State or other jurisdiction of incorporat |
|
| November 12, 2024 |
Email: [***] 4171693.3 Dated 2024 FORGE LIFE SCIENCES NOMINEE 1 LTD AND FORGE LIFE SCIENCES NOMINEE 2 LTD and AUTOLUS LIMITED and AUTOLUS THERAPEUTICS PLC Licence for Alterations relating to The Nucleus Marshgate Stevenage SG1 1FR formerly known as part of The Marshgate Car Park, Stevenage EX-10.3 79025116.1 i TABLE OF CONTENTS No. Heading Page 1. INTERPRETATION AND GENERAL PROVISIONS 1 2. GRANT O |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2024 Autolus Therapeutics plc (Exact name of registrant as specified in its Charter) England and Wales 001-38547 Not applicable (State or other jurisdiction of incorporati |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| November 12, 2024 |
autlex-992cp111124 Autolus.com FDA Approval Conference Call AUCATZYL® (obecabtagene autoleucel) For Investor communication only. Not for use in product promotion. Not for further distribution. EX-99.2 Disclaimer These slides contain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are s |
|
| November 12, 2024 |
autlex-992cp121124 Q3 2024 Financial Results and Business Updates 12 November 2024 Autolus. |
|
| November 12, 2024 |
Email: [***] 4174912.2 Dated FORGE LIFE SCIENCES NOMINEE 1 LTD AND FORGE LIFE SCIENCES NOMINEE 2 LTD - and - AUTOLUS LIMITED and AUTOLUS THERAPEUTICS PLC Deed of Variation relating to premises known as The Nucleus Marshgate Stevenage SG1 1FR formerly known as part of The Marshgate Car Park, Stevenage EX-10.2 4174912.2 i TABLE OF CONTENTS No. Heading Page 1. DEFINITIONS AND INTERPRETATION 1 2. BACK |
|
| November 12, 2024 |
autlex-991pr081124 1 Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) - AUCATZYL is the first CAR T therapy approved by the FDA with no requirement for a REMS program (Risk Evaluation Mitigation Strategy) - Approval based on FELIX clinical trial of obe-cel in adult patien |
|
| November 8, 2024 |
SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Autolus Therapeutics plc (Name of Issuer) Common Stock (Title of Class of Securities) G06630100 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| November 8, 2024 |
JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Autolus Therapeutics plc is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to the Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. |
|
| October 25, 2024 |
Power of Attorney of AMALAR HOLDING s.r.o., dated as of August 5, 2024. EX-99.3 3 ea021861902ex99-3autolus.htm POWER OF ATTORNEY OF AMALAR HOLDING S.R.O., DATED AS OF AUGUST 5, 2024 Exhibit 99.3 POWER OF ATTORNEY KNOW ALL BY THESE PRESENTS, that the undersigned does hereby constitute and appoint Lubomír Král and Radomír Johanna as the undersigned’s true and lawful attorneys-in-fact to, as applicable: (1) execute for and on behalf of the undersigned, in the undersigned |
|
| October 25, 2024 |
SC 13D/A 1 ea0218619-13da10ppfautolus.htm AMENDMENT NO. 10 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 10) AUTOLUS THERAPEUTICS PLC (Name of Issuer) American Depositary Shares, each representing one ordinary share, nominal value $0.000042 per share, and ordinary shares, nominal value $ |
|
| October 25, 2024 |
Joint Filing Agreement, dated as of October 25, 2024. EX-99.1 2 ea021861902ex99-1autolus.htm JOINT FILING AGREEMENT, DATED AS OF OCTOBER 25, 2024 Exhibit 99.1 Joint Filing Agreement Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of any filing required by such party under Section |
|
| September 30, 2024 |
September 30, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F. |
|
| September 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2024 Autolus Therapeutics plc (Exact name of registrant as specified in its Charter) England and Wales 001-38547 Not applicable (State or other jurisdiction of incorpora |
|
| September 26, 2024 |
Developing Next Generation Programmed T Cell Therapies September 2024 Autolus.com EX-99.1 Disclaimer These slides contain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as “may,” “will,” “c |
|
| September 19, 2024 |
1 Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development Officer LONDON, September 19, 2024 - Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced the appointment of Matthias Will, M.D., as Chief Development Officer. Dr. Will is joining Autolus’ executive team and will l |
|
| September 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2024 Autolus Therapeutics plc (Exact name of registrant as specified in its Charter) England and Wales 001-38547 Not applicable (State or other jurisdiction of incorpora |
|
| September 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2024 Autolus Therapeutics plc (Exact name of registrant as specified in its Charter) England and Wales 001-38547 Not applicable (State or other jurisdiction of incorpora |
|
| August 8, 2024 |
Q2 2024 Financial Results and Business Updates 8 August 2024 Autolus.com EX-99.2 Disclaimer These slides contain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as “may,” “will,” “could,” “e |
|
| August 8, 2024 |
Autolus Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates August 8, 2024 at 7:00 AM EDT On track for potential US commercial launch of obe-cel; PDUFA date November 16, 2024 Longer follow up and subset analyses from pivotal FELIX Phase 2 data presented at ASCO and EHA; majority of responders showed durable responses; 40% of patients in ongoing remission without subsequent stem cell transplant (SCT) or other intervention A Market Authorization Application (MAA) for obe-cel in relapsed/refractory r/r adult B-cell Acute Lymphoblastic Leukemia (B-ALL) was submitted to the Medicine and Healthcare products Regulatory Authority (MHRA) in the UK at the end of July 2024. |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 Autolus Therapeutics plc (Exact name of registrant as specified in its Charter) England and Wales 001-38547 Not applicable (State or other jurisdiction of incorporation |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001 |
|
| June 28, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 28, 2024 Autolus Therapeutics plc (Exact name of registrant as specified in its Charter) England and Wales 001-38547 Not applicable (State or other jurisdiction of incorporation |
|
| June 5, 2024 |
1 THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to the action to be taken, please seek your own financial advice from your stockbroker, solicitor, accountant or other appropriately authorised independent financial adviser. If you have recently sold or transferred all of your ordinary shares in Autolus Therapeutics plc, you should forward this document |
|
| June 5, 2024 |
MR A SAMPLE < DESIGNATION> SAMPLE STREET SAMPLE TOWN SAMPLE CITY SAMPLE COUNTY AA11 1AA MR A SAMPLE < Designation> Additional Holder 1 Additional Holder 2 Additional Holder 3 Additional Holder 4 Form of Proxy - Annual General Meeting to be held on 28 June 2024 Kindly Note: This form is issued only to the addressee(s) and is specific to the unique designated account printed hereon. |
|
| June 5, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2024 Autolus Therapeutics plc (Exact name of registrant as specified in its Charter) England and Wales 001-38547 Not applicable (State or other jurisdiction of incorporation o |
|
| June 5, 2024 |
Registered Number 11185179 (England & Wales) Annual Report and financial statements for the year ended 31 December 2023 for Autolus Therapeutics plc Introduction and Contents Autolus Therapeutics plc (the “Company”, “Group” or “Parent Company”) is a public limited company incorporated under the laws of England and Wales and is listed on the Nasdaq Global Select Market (“NASDAQ”). |
|
| June 3, 2024 |
Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO May 31, 2024 at 8:00 AM EDT The majority of patients that responded to obe-cel showed durable responses with the potential for a long-term plateau of survival outcomes 40% patients are in ongoing remission without subsequent |
|
| June 3, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2024 Autolus Therapeutics plc (Exact name of registrant as specified in its Charter) England and Wales 001-38547 Not applicable (State or other jurisdiction of incorporation o |
|
| June 3, 2024 |
American Society of Clinical Oncology Analyst Call 1 June 2024 Autolus.com Disclaimer These slides contain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as “may,” “will,” “could,” “expects |
|
| May 21, 2024 |
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Autolus Therapeutics plc (Name of Issuer) American Depositary Shares, each representing one ordinary share, nominal value $0.000042 per share (Title of Class of Securities) 05280R100 ** (CUSIP Number) John G. Finley Blackstone Inc. 345 Park Aven |
|
| May 17, 2024 |
Q1 2024 Financial Results and Business Updates 17 May 2024 Autolus.com Disclaimer These slides contain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as “may,” “will,” “could,” “expects,” “ |
|
| May 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 00 |
|
| May 17, 2024 |
1 Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates • Longer follow up and subset analyses from the pivotal FELIX Phase 2 data to be presented in oral presentations at ASCO and EHA • Two patients enrolled in Phase 1 Systemic Lupus Erythematosus (SLE) trial; study on track for initial data end of 2024 • Market Authorization Application (MAA) for obe-cel in r/r a |
|
| May 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2024 Autolus Therapeutics plc (Exact name of registrant as specified in its Charter) England and Wales 001-38547 Not applicable (State or other jurisdiction of incorporation o |
|
| May 13, 2024 |
Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call Exhibit 99.1 Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call LONDON, May 13, 2024 — Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it intends to file a Form 12b-25, Notification of Late Filing, with the U.S. Securities and Exchange Co |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 001-38547 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2024 Autolus Therapeutics plc (Exact name of registrant as specified in its Charter) England and Wales 001-38547 Not applicable (State or other jurisdiction of incorporation o |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2024 Autolus Therapeutics plc (Exact name of registrant as specified in its Charter) England and Wales 001-38547 Not applicable (State or other jurisdiction of incorporation |
|
| April 1, 2024 |
1 Autolus Therapeutics Announces Changes to its Board of Directors LONDON, April 1, 2024 – Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces the appointment of Mike Bonney as Chairman of the Board, and Ravi Rao M. |
|
| March 28, 2024 |
As filed with the Securities and Exchange Commission on March 28, 2024 Table of Contents As filed with the Securities and Exchange Commission on March 28, 2024 Registration No. |
|
| March 28, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Autolus Therapeutics plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1)(2) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(6) Equity American Depositary Shares (ADSs) 457(c) 33,333,333 $6. |
|
| March 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 9) AUTOLUS THERAPEUTICS PLC (Name of Issuer) American Depositary Shares, each representing one ordinary share, nominal value $0.000042 per share, and ordinary shares, nominal value $0.000042 per share (Title of Class of Securities) 05280R100** (CUSIP Number) |
|
| March 21, 2024 |
Table of contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to Commission file number: 001-38547 Autolus |
|
| March 21, 2024 |
License and Option Agreement between the registrant and BioNTech SE, dated February 6, 2024. 299246678 v1 [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the Registrant treats as private or confidential. |
|
| March 21, 2024 |
Subsidiaries of the registrant. Exhibit 21.1 Autolus Therapeutics plc List of Subsidiaries Subsidiary Jurisdiction Autolus Holdings (UK) Limited England and Wales Autolus Limited England and Wales Autolus Inc. Delaware Autolus GmbH Germany Autolus Switzerland AG Switzerland |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2024 Autolus Therapeutics plc (Exact name of registrant as specified in its Charter) England and Wales 001-38547 Not applicable (State or other jurisdiction of incorporation |
|
| March 21, 2024 |
erroneously awarded compensation, as required by applicable listing 290949680 v3 AUTOLUS THERAPEUTICS PLC INCENTIVE COMPENSATION RECOUPMENT POLICY 1. INTRODUCTION The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of Autolus Therapeutics plc, a public limited company incorporated under the laws of England and Wales (the “Company”), has determined that it is in the best interests of the Company and its shareholders to |
|
| March 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2024 Autolus Therapeutics plc (Exact name of registrant as specified in its Charter) England and Wales 001-38547 Not applicable (State or other jurisdiction of incorporati |
|
| March 15, 2024 |
Event ID: 138235356103 Event Name: Q4 2023 Autolus Therapeutics PLC Earnings Call Event Date: 2024-03-14T12:30:00 UTC P: Operator;; C: Olivia Manser;Autolus Therapeutics PLC;Investor Relations C: Christian Itin;Autolus Therapeutics PLC;Chief Executive Officer, Executive Director C: Rob Dolski;Autolus Therapeutics PLC;Chief Financial Officer P: James Shin;Deutsche Bank;Analyst P: Unidentified Participant;; P: Gil Blum;Needham & Company Inc. |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2024 Autolus Therapeutics plc (Exact name of registrant as specified in its Charter) England and Wales 001-38547 Not applicable (State or other jurisdiction of incorporation |
|
| March 14, 2024 |
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates March 14, 2024 at 7:00 AM EDT Announced strategic collaboration and equity investment from BioNTech for aggregate proceeds of $250 million upfront, plus underwritten offering of ADSs for $350 million, for gross proceeds of $600 million received in February 2024 Submitted a Biologics License Application (BLA) for obe |
|
| March 14, 2024 |
Full Year 2023 Financial Results and Business Updates March 14, 2024 EX-99.2 Disclaimer 2Developing Next Generation Programmed T Cell Therapies These slides contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, and in some cases can be id |
|
| February 21, 2024 |
SC 13D 1 d782522dsc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Autolus Therapeutics plc (Name of Issuer) Ordinary shares, nominal value $0.000042 per share (including ordinary shares represented by American Depositary Shares)** (Title of Class of Securities) 05280R100*** (CUSIP Numbe |
|
| February 14, 2024 |
SC 13G/A 1 tm245955d3sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Autolus Therapeutics plc (Name of Issuer) Ordinary Shares, nominal value $0.000042 per share** (Title of Class of Securities) 05280R100*** (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of t |
|
| February 14, 2024 |
SC 13G/A 1 armistice-autl123123a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Autolus Therapeutics, plc (Name of Issuer) American Depository Shares, each representing one ordinary share, nominal value $0.000042 per share (Title of Class of Securities) 05280R100 (CUSIP Number) December 31, 2023 |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 13, 2024 |
EX-99.1 2 d783202dex991.htm EX-99.1 Exhibit 99.1 AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Ordinary Shares (represented by ADS, each of which represents one Ordinary Share) of Autolus Th |
|
| February 13, 2024 |
Developing Next Generation Programmed T Cell Therapies February 2024 Exhibit 99.1 Disclaimer Developing Next Generation Programmed T Cell Therapies These slides contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, and in some cases can b |
|
| February 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2024 Autolus Therapeutics plc (Exact name of registrant as specified in its Charter) England and Wales 001-38547 Not applicable (State or other jurisdiction of incorporat |
|
| February 13, 2024 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* Autolus Therapeutics plc (Name of Issuer) American Depositary Shares and Ordinary Shares, nominal value $0.000042 per share (Title of Class of Securities) 05280R 100** (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this |
|
| February 9, 2024 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Autolus Therapeutics plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid Equity Ordinary shares, nominal value $0. |
|
| February 9, 2024 |
58,333,336 American Depositary Shares Representing Ordinary Shares Table of Contents Filed Pursuant to Rule 424(b)(5) Registration File No. 333-276942 PROSPECTUS SUPPLEMENT (To Prospectus Dated February 8, 2024) 58,333,336 American Depositary Shares Representing Ordinary Shares We are offering 58,333,336 of our American Depositary Shares, or ADSs. Each ADS represents one ordinary share with a nominal value of $0.000042 per share. The ADSs may be evidenced by Amer |
|
| February 8, 2024 |
Regulation FD Disclosure, Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2024 Autolus Therapeutics plc (Exact name of registrant as specified in its Charter) England and Wales 001-38547 Not applicable (State or other jurisdiction of incorporati |
|
| February 8, 2024 |
Exhibit 4.7 Autolus Therapeutics plc, Issuer AND [TRUSTEE], Trustee FORM OF INDENTURE Dated as of [•], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certific |
|
| February 8, 2024 |
Exhibit 1.1 Autolus Therapeutics plc American Depositary Shares Representing Ordinary Shares Underwriting Agreement February 8, 2024 Jefferies LLC Truist Securities, Inc. as representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto Jefferies LLC 520 Madison Avenue New York, New York 10022 Truist Securities, Inc. 3333 Peachtree Road NE 11th Floor Atlanta, GA 303 |
|
| February 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2024 Autolus Therapeutics plc (Exact name of registrant as specified in its Charter) England and Wales 001-38547 Not applicable (State or other jurisdiction of incorporati |
|
| February 8, 2024 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. Exhibit 4.10 AUTOLUS THERAPEUTICS PLC AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF AUTOLUS THERAPEUTICS PLC FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between AUTOLUS THERAPEUTICS PLC, a public limited company incorporated under the laws of England and Wales under company number 11185179 and |
|
| February 8, 2024 |
Letter Agreement between the registrant and BioNTech SE, dated February 6, 2024. Exhibit 10.3 Execution Version AUTOLUS THERAPEUTICS PLC The MediaWorks 191 Wood Lane London, W12 7FP, United Kingdom 6 February 2024 BioNTech SE An der Goldgrube 12 55131 Mainz Germany Re: Director Nomination and Shareholder Restrictions This letter agreement (this “Letter Agreement”) confirms the agreement between Autolus Therapeutics plc (registered number 11185179), a public limited company inc |
|
| February 8, 2024 |
Securities Purchase Agreement between the registrant and BioNTech SE, dated February 6, 2024. Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of February 6, 2024 by and among AUTOLUS THERAPEUTICS PLC (registered number 11185179), a public limited company incorporated in England and Wales whose registered office is at The MediaWorks, 191 Wood Lane, London W12 7FP, United Kingdom (the “Company”), a |
|
| February 8, 2024 |
Registration Rights Agreement between the registrant and BioNTech SE, dated February 6, 2024. Exhibit 10.2 Execution Version AUTOLUS THERAPEUTICS PLC REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of February 6, 2024 by and between Autolus Therapeutics plc, a public limited company incorporated under the laws of England and Wales (the “Company”), and BioNTech SE, a Societas Europaea organized and existing under the laws of Ge |
|
| February 8, 2024 |
Form of Ordinary Share Warrant Agreement and Warrant Certificate. Exhibit 4.9 AUTOLUS THERAPEUTICS PLC AND , AS WARRANT AGENT FORM OF ORDINARY SHARES WARRANT AGREEMENT DATED AS OF AUTOLUS THERAPEUTICS PLC FORM OF ORDINARY SHARES WARRANT AGREEMENT THIS ORDINARY SHARES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between AUTOLUS THERAPEUTICS PLC, a public limited company incorporated under the laws of England and Wales under company number 11185179 and h |
|
| February 8, 2024 |
As filed with the Securities and Exchange Commission on February 8, 2024 S-3ASR Table of Contents As filed with the Securities and Exchange Commission on February 8, 2024 Registration No. |
|
| February 8, 2024 |
Exhibit 99.1 BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs • Strategic alliance leverages manufacturing and commercial infrastructure as well as technology with the aim to advance both companies’ autologous CAR-T programs towards market, pending market authorization • BioNTech secures the right to utilize Autolus’ manufa |
|
| February 8, 2024 |
Autolus Announces Pricing of Underwritten Offering Exhibit 99.1 Autolus Announces Pricing of Underwritten Offering LONDON – 8 February 2024 – Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the pricing of an underwritten offering in the United States of 58,333,336 American Depositary Shares (“ADSs”) representing 58,333,336 ordinary shares at |
|
| February 8, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Autolus Therapeutics plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title(1) Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Ordinary shares, nominal value $0. |
|
| January 31, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Autolus Therapeutics plc (Name of Issuer) Ordinary shares, nominal value $0.000042 per share (Title of Class of Securities) 05280R100** (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate th |
|
| January 26, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2024 Autolus Therapeutics plc (Exact name of registrant as specified in its Charter) England and Wales 001-38547 Not applicable (State or other jurisdiction of incorporati |
|
| January 26, 2024 |
Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL) January 22, 2024 at 7:00 AM EST PDUFA Goal date is November 16, 2024 Company on track to submit a marketing authorization application to the European Medicines Agency (EMA) in the first half of 2024 LONDON, Jan. |
|
| January 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2024 Autolus Therapeutics plc (Exact name of registrant as specified in its Charter) England and Wales 001-38547 Not applicable (State or other jurisdiction of incorporatio |
|
| January 10, 2024 |
Autolus Therapeu�cs announces the appointment of Robert W. Azelby to its Board of Directors LONDON, January 10, 2024 - Autolus Therapeu�cs plc (Nasdaq: AUTL), a clinical-stage biopharmaceu�cal company developing next-genera�on programmed T cell therapies, today announced the appointment of Robert W. Azelby to the Board of Directors. Mr. Azelby brings more than 30 years of biopharmaceu�cal leadersh |
|
| December 22, 2023 |
pressreleasedateddecembe Autolus Therapeu�cs Announces Changes to its Board of Directors - Appointment of Elisabeth (“Lis”) Leiderman, M. |
|
| December 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2023 Autolus Therapeutics plc (Exact name of registrant as specified in its Charter) England and Wales 001-38547 Not applicable (State or other jurisdiction of incorporat |
|
| December 11, 2023 |
ACTIVE/112974591.2 Exhibit 99.1 Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023 - Pooled analysis of the FELIX Phase Ib/II study demonstrated prolonged event free survival and low overall immunotoxicity across all cohorts in r/r B-ALL, and particularly in patients with low leukemic burden at lymphodepletion - Longer-term data from |
|
| December 11, 2023 |
ashcorporatepresentation Developing Next Generation Programmed T Cell Therapies ASH Analyst Meeting and Webcast December 2023 Disclaimer 2Developing Next Generation Programmed T Cell Therapies These slides contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. |
|
| December 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2023 Autolus Therapeutics plc (Exact name of registrant as specified in its Charter) England and Wales 001-38547 Not applicable (State or other jurisdiction of incorporati |
|
| November 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2023 Autolus Therapeutics plc (Exact name of registrant as specified in its Charter) England and Wales 001-38547 Not applicable (State or other jurisdiction of incorporat |
|
| November 27, 2023 |
1 Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL) • BLA submission includes results from pivotal Phase 2 FELIX study evaluating obe-cel in relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL) • Company |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| November 9, 2023 |
Confidential 1 of 16 AMENDMENT NO. 2 TO SUPPLY AGREEMENT This Amendment No. 2 to Supply Agreement (the “Amendment”) between the Parties is made and effective as of the date of the last signature (the “Amendment Effective Date”), by and between: Autolus Limited, a corporation having its principal place of business at MediaWorks, 191 Wood Lane, White City, London, W12 7FP, United Kingdom (“Autolus”) |
|
| November 9, 2023 |
19 September Dated 2023 FORGE LIFE SCIENCES NOMINEE 1 LIMITED AND FORGE LIFE SCIENCES NOMINEE 2 LIMITED and AUTOLUS LIMITED and AUTOLUS THERAPEUTICS PLC LEASE OF THE NUCLEUS MARSHGATE STEVENAGE SG1 1FR FORMERLY KNOWN AS PART OF THE MARSHGATE CAR PARK, STEVENAGE 76907807. |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 Autolus Therapeutics plc (Exact name of registrant as specified in its Charter) England and Wales 001-38547 Not applicable (State or other jurisdiction of incorporati |
|
| November 3, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Autolus Therapeutics plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary shares, nominal value $0. |
|
| November 3, 2023 |
As filed with the U.S. Securities and Exchange Commission on November 3, 2023 S-8 As filed with the U.S. Securities and Exchange Commission on November 3, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Autolus Therapeutics plc (Exact name of registrant as specified in its charter) England and Wales Not applicable (State or other jurisdiction of Incorporation |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2023 Commission File Number: 001-38547 Autolus Therapeutics plc (Translation of registrant’s name into English) The MediaWorks 191 Wood Lane London W12 7FP United Kingdom (Address of p |
|
| November 2, 2023 |
Autolus Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates November 2, 2023 at 7:12 AM EDT Obe-cel, a potentially transformational treatment for relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL), on track for a Biologics License Application (BLA) submission to the US Food & Drug Administration (FDA) by end of 2023 Updated clinical data at the Ame |
|
| November 2, 2023 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of our financial condition and results of operations should be read together with the unaudited condensed consolidated financial statements and the related notes to those statements included as Exhibit 99.1 to this Report on Form 6-K submitted to the Securities a |
|
| November 2, 2023 |
Exhibit 99.1 INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Condensed Consolidated Balance Sheets as of September 30, 2023 (Unaudited) and December 31, 2022 2 Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2023 and 2022 (Unaudited) 3 Condensed Consolidated Statements of Shareholders’ Equity for the Three and Nine Month |
|
| August 7, 2023 |
As filed with the U.S. Securities and Exchange Commission on August 7, 2023 S-8 As filed with the U.S. Securities and Exchange Commission on August 7, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Autolus Therapeutics plc (Exact name of registrant as specified in its charter) England and Wales Not applicable (State or other jurisdiction of Incorporation or |
|
| August 7, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Autolus Therapeutics plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary shares, nominal value $0. |
|
| August 3, 2023 |
pressreleaseasofaugust03 1 Autolus Therapeutics Reports Second Quarter 2023 Financial Results and Operational Progress - Obe-cel, a potentially transformational treatment for relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL), on track for a Biologics License Application (BLA) submission to the US Food & Drug Administration (FDA) by end of 2023 - Pivotal FELIX data at ASCO s |
|
| August 3, 2023 |
Exhibit 99.1 INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Condensed Consolidated Balance Sheets as of June 30, 2023 (Unaudited) and December 31, 2022 2 Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Six Months Ended June 30, 2023 and 2022 (Unaudited) 3 Condensed Consolidated Statements of Shareholders’ Equity for the Three and Six Months Ended June |
|
| August 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2023 Commission File Number: 001-38547 Autolus Therapeutics plc (Translation of registrant’s name into English) The MediaWorks 191 Wood Lane London W12 7FP United Kingdom (Address of pri |
|
| August 3, 2023 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of our financial condition and results of operations should be read together with the unaudited condensed consolidated financial statements and the related notes to those statements included as Exhibit 99.1 to this Report on Form 6-K submitted to the Securities a |
|
| July 21, 2023 |
pressreleasedatedjuly192 Autolus Therapeutics announces appointment of Robert F. Dolski as Chief Financial Officer July 19, 2023 at 7:00 AM EDT - Veronica Hersberger appointed as Senior Vice President, Medical Affairs - Miranda Neville promoted to Senior Vice President, Project Management and will continue to lead the obe-cel program LONDON, July 19, 2023 (GLOBE NEWSWIRE) - Autolus Therapeutics pl |
|
| July 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of July 2023 Commission File Number: 001-38547 Autolus Therapeutics plc (Translation of registrant’s name into English) The MediaWorks 191 Wood Lane London W12 7FP United Kingdom (Address of princ |
|
| July 10, 2023 |
Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the ordinary shares, nominal value $0. |
|
| July 10, 2023 |
AUTL / Autolus Therapeutics plc - ADR / Paradigm Biocapital Advisors LP - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Autolus Therapeutics plc (Name of Issuer) Ordinary shares, nominal value $0.000042 per share** (Title of Class of Securities) 05280R100*** (CUSIP Number) June 30, 2023 (Date of Event Which Requires Filing of this statement) Check the appropriate box to de |
|
| July 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2023 Commission File Number: 001-38547 Autolus Therapeutics plc (Translation of registrant’s name into English) The MediaWorks 191 Wood Lane London W12 7FP United Kingdom (Address of pri |
|
| July 7, 2023 |
ex991annualreportandacco |
|
| July 7, 2023 |
ex992noticeofannualgener 1 THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. |
|
| July 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2023 Commission File Number: 001-38547 Autolus Therapeutics plc (Translation of registrant’s name into English) The MediaWorks 191 Wood Lane London W12 7FP United Kingdom (Address of princ |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2023 Commission File Number: 001-38547 Autolus Therapeutics plc (Translation of registrant’s name into English) The MediaWorks 191 Wood Lane London W12 7FP United Kingdom (Address of princ |
|
| June 20, 2023 |
pressreleasedatedjune202 Autolus Therapeutics strengthens its Board with the appointment of Dr. |
|
| June 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2023 Commission File Number: 001-38547 Autolus Therapeutics plc (Translation of registrant’s name into English) The MediaWorks 191 Wood Lane London W12 7FP United Kingdom (Address of princ |
|
| June 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2023 Commission File Number: 001-38547 Autolus Therapeutics plc (Translation of registrant’s name into English) The MediaWorks 191 Wood Lane London W12 7FP United Kingdom (Address of princ |
|
| June 6, 2023 |
ex992noticeofannualgener 1 THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. |
|
| June 6, 2023 |
ex991annualreportandacco |
|
| June 6, 2023 |
ex993formofproxy MR A SAMPLE < DESIGNATION> SAMPLE STREET SAMPLE TOWN SAMPLE CITY SAMPLE COUNTY AA11 1AA MR A SAMPLE < Designation> Additional Holder 1 Additional Holder 2 Additional Holder 3 Additional Holder 4 Form of Proxy - Annual General Meeting to be held on 30 June 2023 Kindly Note: This form is issued only to the addressee(s) and is specific to the unique designated account printed hereon. |
|
| June 6, 2023 |
ex-991pressreleasedatedj Autolus Therapeutics Presents Positive Results from Pivotal Phase 2 FELIX study in adult r/r B-ALL at ASCO June 2, 2023 76% of patients treated with obe-cel in the FELIX study achieved a response (CR/CRi), primary endpoint has been met based on previously communicated interim analysis Potential best in class tolerability, with very low levels of high-grade CRS and ICANS Robust and reliable manufacturing and logistics, with 84% of enrolled patients receiving obe-cel Analyst call to be held today, June 2, 2023 at 4. |
|
| May 4, 2023 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of our financial condition and results of operations should be read together with the unaudited condensed consolidated financial statements and the related notes to those statements included as Exhibit 99.1 to this Report on Form 6-K submitted to the Securities a |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2023 Commission File Number: 001-38547 Autolus Therapeutics plc (Translation of registrant’s name into English) The MediaWorks 191 Wood Lane London W12 7FP United Kingdom (Address of princi |
|
| May 4, 2023 |
pressrelease04may2023 Autolus Therapeutics Reports First Quarter 2023 Financial Results and Operational Progress May 4, 2023 Obe-cel, a potentially transformational treatment for relapsed/refractory (r/r) B-cell Acute Lymphoblastic Leukemia (ALL), on track for next data update at ASCO and EHA, with a Biologics License Application (BLA) submission to the US FDA planned by end of the year Establishi |
|
| May 4, 2023 |
Exhibit 99.1 INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Condensed Consolidated Balance Sheets as of March 31, 2023 (Unaudited) and December 31, 2022 2 Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three Months Ended March 31, 2023 and 2022 (Unaudited) 3 Condensed Consolidated Statements of Shareholders’ Equity for the Three Months Ended March 31, 2023 and |
|
| March 20, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Autolus Therapeutics plc (Name of Issuer) Ordinary shares, nominal value $0.000042 per share (Title of Class of Securities) 05280R100** (CUSIP Number) March 9, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule |
|
| March 20, 2023 |
JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) EXHIBIT 99.1 JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The unders |
|
| March 14, 2023 |
pressreleasedatedmarch14 Autolus Therapeutics announces resignation of Chief Financial Officer March 14, 2023 - Dr. |
|
| March 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2023 Commission File Number: 001-38547 Autolus Therapeutics plc (Translation of registrant’s name into English) The MediaWorks 191 Wood Lane London W12 7FP United Kingdom (Address of prin |
|
| March 7, 2023 |
Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Lucinda C. |
|
| March 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| March 7, 2023 |
Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Christian Itin, certify that: 1. |
|
| March 7, 2023 |
Consent of Independent Registered Public Accounting Firm Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: (1)Registration Statement (Form S-8 No. |
|
| March 7, 2023 |
Certification by the Principal Executive Officer and Principal Financial Officer pursuant to 18 U. |
|
| March 1, 2023 |
Exhibit (e) Rule 466 Certification The depositary, Citibank, N.A., represents and certifies the following: (i) That it previously had filed a registration statement on Form F-6 (Registration No. 333-260904), which the U.S. Securities and Exchange Commission declared effective, with terms of deposit identical to the terms of deposit of this Form F-6 Registration Statement and (ii) That its ability |
|
| March 1, 2023 |
Exhibit (b)(i) Autolus Therapeutics plc As of November 16, 2021 Citibank, N.A. - ADR Department 388 Greenwich Street New York, New York 10013 Re: Restricted ADSs (CUSIP No.: 05280R993) Ladies and Gentlemen: Reference is made to the Deposit Agreement, dated as of June 26, 2018, as amended and supplemented from time to time (the “Deposit Agreement”), by and among Autolus Therapeutics plc, a public l |
|
| March 1, 2023 |
and Citibank, N.A. BLACKSTONE – WARRANT Exhibit (b)(iii) SERIES EXHIBIT B to Restricted ADS Letter Agreement, dated as of November 16, 2021 (the “Restricted ADS Letter Agreement”), by and between Autolus Therapeutics plc and Citibank, N. |
|
| March 1, 2023 |
and Citibank, N.A. BLACKSTONE – PIPE SECURITIES PURCHASE AGREEMENT Exhibit (b)(ii) SERIES EXHIBIT A to Restricted ADS Letter Agreement, dated as of November 16, 2021 (the “Restricted ADS Letter Agreement”), by and between Autolus Therapeutics plc and Citibank, N. |
|
| March 1, 2023 |
Exhibit (d) March 1, 2023 Citibank, N.A. – ADR Department 388 Greenwich Street New York, New York 10013 Ladies and Gentlemen: We refer to the Registration Statement on Form F-6 (the “Registration Statement”) to be filed with the Securities and Exchange Commission (the “SEC”) by the legal entity created by the Deposit Agreement (as hereinafter defined) for the purpose of registering under the Unite |
|
| March 1, 2023 |
As filed with the Securities and Exchange Commission on March 1, 2023 Registration No. |
|
| February 14, 2023 |
AUTL / Autolus Therapeutics PLC / Deep Track Capital, LP Passive Investment SC 13G/A 1 deeptrack-autl123122a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Autolus Therapeutics PLC (Name of Issuer) American Depositary Shares, each representing one ordinary share, nominal value $0.000042 per share (Title of Class of Securities) 05280R100 (CUSIP Number) December 31, 2022 |
|
| February 14, 2023 |
AUTL / Autolus Therapeutics PLC / Nantahala Capital Management, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Autolus Therapeutics plc (Name of Issuer) American Depository Shares, each representing one ordinary share, nominal value $0.000042 per share (Title of Class of Securities) 05280R100 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing o |
|
| February 14, 2023 |
SC 13G/A 1 d437783dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Autolus Therapeutics plc (Name of Issuer) Ordinary Shares (Title of Class of Securities) 05280R100** (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| February 14, 2023 |
AUTL / Autolus Therapeutics PLC / ARMISTICE CAPITAL, LLC Passive Investment SC 13G 1 armistice-autl123122.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Autolus Therapeutics, plc (Name of Issuer) American Depository Shares, each representing one ordinary share, nominal value $0.000042 per share (Title of Class of Securities) 05280R100 (CUSIP Number) December 31, 2022 (Date |
|
| February 14, 2023 |
/s/ Martin Murphy Martin Murphy EX-99.1 Exhibit 99.1 AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Ordinary Shares (represented by ADS, each of which represents one Ordinary Share) of Autolus Therapeutics plc and further a |
|
| February 14, 2023 |
AUTL / Autolus Therapeutics PLC / Syncona Portfolio Ltd - SC 13G/A Passive Investment SC 13G/A 1 d411686dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* Autolus Therapeutics plc (Name of Issuer) American Depositary Shares and Ordinary Shares, nominal value $0.000042 per share (Title of Class of Securities) 05280R 100** (CUSIP Number) December 31, 2022 (Date of Event |
|
| February 13, 2023 |
AUTL / Autolus Therapeutics PLC / Capital World Investors - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Autolus Therapeutics PLC (Name of Issuer) Common Stock (Title of Class of Securities) 05280R100 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| January 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of January 2023 Commission File Number: 001-38547 Autolus Therapeutics plc (Translation of registrant’s name into English) The MediaWorks 191 Wood Lane London W12 7FP United Kingdom (Address of pr |
|
| January 23, 2023 |
pressreleasedatedjanuary Autolus Therapeutics announces Board changes January 20, 2023 LONDON, Jan. |
|
| December 21, 2022 |
Autolus Announces Partial Exercise of Underwriters’ Option to Purchase Additional ADSs Exhibit 99.1 Autolus Announces Partial Exercise of Underwriters? Option to Purchase Additional ADSs LONDON ? 21 December 2022 ? Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, announced today that the underwriters of its previously announced public offering of American Depositary Shares, or ADSs, which clos |
|
| December 21, 2022 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2022 Commission File Number: 001-38547 Autolus Therapeutics plc (Translation of registrant’s name into English) The MediaWorks 191 Wood Lane London W12 7FP United Kingdom (Address |
|
| December 19, 2022 |
AUTL / Autolus Therapeutics PLC / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| December 13, 2022 |
AUTL / Autolus Therapeutics PLC / Blackstone Group Inc - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Autolus Therapeutics plc (Name of Issuer) American Depositary Shares, each representing one ordinary share, nominal value $0.000042 per share (Title of Class of Securities) 05280R100 ** (CUSIP Number) John G. Finley Blackstone Inc. 345 Park Avenue New Yo |
|
| December 13, 2022 |
EXHIBIT A The Schedule 13G to which this attachment is appended is filed by Qatar Investment Authority on behalf of itself and the following subsidiaries: Qatar Holding LLC |
|
| December 13, 2022 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) * AUTOLUS THERAPEUTICS PLC (Name of Issuer) American Depositary Shares, each representing one ordinary share, par value $0.000042 per share (Title of Class of Securities) 05280R100** (CUSIP Number) December 9, 2022 (Date of Event Which Requires Filing this Statement) Ch |
|
| December 13, 2022 |
EXHIBIT B CERTIFICATE OF INCUMBENCY I, Ahmad Mohammed F Q Al-Khanji, Chief of Legal and General Counsel, of Qatar Investment Authority, established by Emiri Decision No 22 in 2005, with its registered office at, Ooredoo Tower (Building 14), Al Dafna Street (Street 801), Al Dafna (Zone 61), Doha, State of Qatar, do hereby confirm that Andrew Watkins is the duly appointed Associate General Counsel, Compliance, an officer of the Qatar Investment Authority, and as such, is authorized to sign regulatory filings on behalf of the Qatar Investment Authority. |
|
| December 12, 2022 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2022 Commission File Number: 001-38547 Autolus Therapeutics plc (Translation of registrant’s name into English) The MediaWorks 191 Wood Lane London W12 7FP United Kingdom (Address |
|
| December 12, 2022 |
75,000,000 American Depositary Shares Representing 75,000,000 Ordinary Shares 424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-258556 PROSPECTUS SUPPLEMENT (To Prospectus Dated August 19, 2021) 75,000,000 American Depositary Shares Representing 75,000,000 Ordinary Shares We are offering 75,000,000 of our American Depositary Shares, or ADSs. Each ADS represents one ordinary share with a nominal value of $0.000042 per share. The ADSs may be eviden |
|
| December 12, 2022 |
EX-1.1 Exhibit 1.1 Autolus Therapeutics plc American Depositary Shares Representing Ordinary Shares Underwriting Agreement December 8, 2022 Jefferies LLC William Blair & Company, L.L.C. Wells Fargo Securities, LLC as representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto Jefferies LLC 520 Madison Avenue New York, New York 10022 William Blair & Company, L.L.C |
|
| December 12, 2022 |
Autolus Announces Pricing of Public Offering EX-99.1 Exhibit 99.1 Autolus Announces Pricing of Public Offering LONDON – 8 December 2022 – Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the pricing of its previously announced underwritten public offering in the United States of 75,000,000 American Depositary Shares (“ADSs”) representin |
|
| December 8, 2022 |
SUBJECT TO COMPLETION, DATED DECEMBER 8, 2022 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration File No. 333-258556 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an off |
|
| December 8, 2022 |
Material U.S. Federal Income Tax Considerations for U.S. Holders EX-99.1 Exhibit 99.1 TAXATION The following summary contains a description of material U.K. and U.S. federal income tax consequences of the acquisition, ownership and disposition of our ADSs. This summary should not be considered a comprehensive description of all the tax considerations that may be relevant to beneficial owners of ADSs. Material U.S. Federal Income Tax Considerations for U.S. Hold |
|
| December 8, 2022 |
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2022 Commission File Number: 001-38547 Autolus Therapeutics plc (Translation of registrant’s name into English) The MediaWorks 191 Wood Lane London W12 7FP United Kingdom (Address |
|
| December 8, 2022 |
Autolus Announces Proposed Public Offering in the United States EX-99.2 Exhibit 99.2 Autolus Announces Proposed Public Offering in the United States LONDON – 8 December 2022 – Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has commenced an underwritten public offering of American Depositary Shares (“ADSs”), each ADS representing one ordinary sha |
|
| November 21, 2022 |
6-K/A 1 autolus-300920226ka.htm 6-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2022 Commission File Number: 001-38547 Autolus Therapeutics plc (Translation of registrant’s name into English) The MediaWorks 191 Wood Lane Lon |
|
| November 21, 2022 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of our financial condition and results of operations should be read together with the unaudited condensed consolidated financial statements and the related notes to those statements included as Exhibit 99.1 to this Report on Form 6-K submitted to the Securities a |
|
| November 3, 2022 |
1 Autolus Therapeutics Reports Third Quarter 2022 Financial Results and Operational Progress - Pivotal FELIX Phase 2 clinical trial of obe-cel in relapsed/refractory (r/r) Acute Lymphoblastic Leukemia (ALL) on track for Q4 2022 update - Commercial manufacturing site build on schedule for handover of first clean rooms to Autolus in Q4 2022 - Post-period end announcements: Bristol Myers Squibb licen |
|
| November 3, 2022 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT?S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of our financial condition and results of operations should be read together with the unaudited condensed consolidated financial statements and the related notes to those statements included as Exhibit 99.1 to this Report on Form 6-K submitted to the Securities a |
|
| November 3, 2022 |
Exhibit 99.1 INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Condensed Consolidated Balance Sheets as of September 30, 2022 and December 31, 2021 (Unaudited) 2 Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2022 and 2021 (Unaudited) 3 Condensed Consolidated Statements of Shareholders? Equity for the Three and Nine Month |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of November 2022 Commission File Number: 001-38547 Autolus Therapeutics plc (Translation of registrant’s name into English) The MediaWorks 191 Wood Lane London W12 7FP United Kingdom (Address of p |
|
| October 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 8) AUTOLUS THERAPEUTICS PLC (Name of Issuer) American Depositary Shares, each representing one ordinary share, nominal value $0.000042 per share, and ordinary shares, nominal value $0.000042 per share (Title of Class of Securities) 05280R100** (CUSIP Number) |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of August 2022 Commission File Number: 001-38547 Autolus Therapeutics plc (Translation of registrant?s name into English) The MediaWorks 191 Wood Lane London W12 7FP United Kingdom (Address of pri |
|
| August 4, 2022 |
Exhibit 99.1 INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Condensed Consolidated Balance Sheets as of June 30, 2022 and December 31, 2021 (Unaudited) 2 Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Six Months Ended June 30, 2022 and 2021 (Unaudited) 3 Condensed Consolidated Statements of Shareholders? Equity for the Three and Six Months Ended June |
|
| August 4, 2022 |
Autolus Therapeutics Reports Second Quarter 2022 Financial Results and Operational Progress August 4, 2022 - Conference call to be held on August 4, 2022 at 8:30 am ET/1:30 pm BST - LONDON, Aug. |
|
| August 4, 2022 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT?S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of our financial condition and results of operations should be read together with the unaudited condensed consolidated financial statements and the related notes to those statements included as Exhibit 99.1 to this Report on Form 6-K submitted to the Securities a |
|
| July 1, 2022 |
Annual Report and Accounts for the 12-month period ended December 31, 2021 Registered Number 11185179 (England & Wales) Annual Report and Accounts for the year ended 31 December 2021 for Autolus Therapeutics plc AUTOLUS THERAPEUTICS PLC Introduction and Contents Autolus Therapeutics plc (the ?Company?, ?Group? or ?Parent Company?) is a public limited company incorporated under the laws of England and Wales and is listed on the Nasdaq Global Select Market (?NASDAQ?). |
|
| July 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of June 2022 Commission File Number: 001-38547 Autolus Therapeutics plc (Translation of registrant?s name into English) The MediaWorks 191 Wood Lane London W12 7FP United Kingdom (Address of princ |
|
| June 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2022 (Commission File No. 001-38547) Autolus Therapeutics plc (Translation of registrant?s name into English) The MediaWorks 191 Wood Lane London W12 7FP United Kingdom (Address of registrant |
|
| June 1, 2022 |
Exhibit 99.1 THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to the action to be taken, please seek your own financial advice from your stockbroker, solicitor, accountant or other appropriately authorised independent financial adviser. If you have recently sold or transferred all of your shares in Autolus Therapeutics plc, you should forward this docume |
|
| May 18, 2022 |
12,180,333 American Depositary Shares Representing 12,180,333 Ordinary Shares Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-264650 PROSPECTUS 12,180,333 American Depositary Shares Representing 12,180,333 Ordinary Shares This prospectus relates to the resale by the selling securityholders identified in this prospectus, or the selling securityholders, of up to 12,180,333 American Depositary Shares, or ADSs, representing 12,180,333 ordinary shares of |
|
| May 13, 2022 |
The MediaWorks 191 Wood Lane White City London W12 7FP United Kingdom VIA EDGAR The MediaWorks 191 Wood Lane White City London W12 7FP United Kingdom VIA EDGAR May 13, 2022 U. |
|
| May 5, 2022 |
Material U.S. Federal Income Tax Considerations for U.S. Holders Exhibit 99.3 TAXATION The following summary contains a description of material U.K. and U.S. federal income tax consequences of the acquisition, ownership and disposition of our ADSs. This summary should not be considered a comprehensive description of all the tax considerations that may be relevant to beneficial owners of ADSs Material U.S. Federal Income Tax Considerations for U.S. Holders The f |
|
| May 5, 2022 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.2 MANAGEMENT?S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of our financial condition and results of operations should be read together with the unaudited condensed consolidated financial statements and the related notes to those statements included as Exhibit 99.1 to this Report on Form 6-K submitted to the Securities a |
|
| May 5, 2022 |
Exhibit 99.1 INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Condensed Consolidated Balance Sheets as of March 31, 2022 and December 31, 2021 (Unaudited) 2 Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three Months Ended March 31, 2022 and 2021 (Unaudited) 3 Condensed Consolidated Statements of Shareholders? Equity for the Three Months Ended March 31, 2022 and |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of May 2022 Commission File Number: 001-38547 Autolus Therapeutics plc (Translation of registrant?s name into English) The MediaWorks 191 Wood Lane London W12 7FP United Kingdom (Address of princi |
|
| May 4, 2022 |
As filed with the Securities and Exchange Commission on May 3, 2022 Table of Contents As filed with the Securities and Exchange Commission on May 3, 2022 Registration No. |
|
| May 4, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form F-3 (Form Type) Autolus Therapeutics plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1)(2) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(6) Equity American Depositary Shares (ADSs) 457(c) 12,180,333 $3. |
|
| May 3, 2022 |
21,250,917 American Depositary Shares Representing 21,250,917 Ordinary Shares Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-264304 PROSPECTUS 21,250,917 American Depositary Shares Representing 21,250,917 Ordinary Shares This prospectus relates to the resale by the selling securityholders identified in this prospectus, or the selling securityholders, of up 21,250,917 American Depositary Shares, or ADSs, representing 21,250,917 ordinary shares of Aut |
|
| April 26, 2022 |
The MediaWorks 191 Wood Lane White City London W12 7FP United Kingdom VIA EDGAR The MediaWorks 191 Wood Lane White City London W12 7FP United Kingdom VIA EDGAR April 26, 2022 U. |
|
| April 15, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form F-3 (Form Type) Autolus Therapeutics plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1)(2) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(6) Equity American Depositary Shares (ADSs) 457(c) 21,250,917 $4. |
|
| April 15, 2022 |
As filed with the Securities and Exchange Commission on April 14, 2022 Table of Contents As filed with the Securities and Exchange Commission on April 14, 2022 Registration No. |
|
| March 10, 2022 |
Consent of Independent Registered Public Accounting Firm Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the following Registration Statements: (1)Registration Statement (Form S-8 No. |
|
| March 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| March 10, 2022 |
ACTIVE/115687690.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENTS, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. -i- COLLABORATION AND FINANCING AGREEMENT by and between AUTOLUS LIMITED AND BXLS V ? AUTOBAHN L.P. ACTIVE/115687690.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENTS, |
|
| March 10, 2022 |
Certification by the Principal Executive Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Christian Itin, certify that: 1. |
|
| March 10, 2022 |
Certification by the Principal Financial Officer pursuant to Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Andrew J. |
|
| March 10, 2022 |
Certification by the Principal Executive Officer and Principal Financial Officer pursuant to 18 U. |
|
| February 14, 2022 |
AUTL / Autolus Therapeutics PLC / Nantahala Capital Management, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Autolus Therapeutics plc (Name of Issuer) American Depositary Shares and Ordinary Shares, nominal value $0.000042 per share (Title of Class of Securities) 05280R100 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) C |
